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Abstract
Background
Oxytocin is the gold standard drug for the prevention of postpartum haemorrhage, but limita-
tions in cold chain systems in resource-constrained settings can severely compromise the
quality of oxytocin product available in these environments. This study investigated the per-
spectives and practices of stakeholders in low and lower-middle income countries towards
oxytocin, its storage requirements and associated barriers, and the quality of product
available.
Methods
Qualitative inquiries were undertaken in Ethiopia, India and Myanmar, where data was col-
lected through Focus Group Discussions (FGDs) and In-Depth Interviews (IDIs). A total of
12 FGDs and 106 IDIs were conducted with 158 healthcare providers (pharmacists, mid-
wives, nurses, doctors and obstetricians) and 40 key informants (supply chain experts, pro-
gram managers and policy-makers). Direct observations of oxytocin storage practices and
cold chain resources were conducted at 51 healthcare facilities. Verbatim transcripts of
FGDs and IDIs were translated to English and analysed according to a thematic content
analysis framework.
Findings
Stakeholder awareness of oxytocin heat sensitivity and the requirement for cold storage of
the drug was widespread in Ethiopia but more limited in Myanmar and India. A consistent
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finding across all study regions was the significant barriers to maintaining a consistent cold
chain, with the lack of refrigeration facilities and unreliability of electricity cited as major chal-
lenges. Perceptions of compromised oxytocin quality were expressed by some stakeholders
in each country.
Conclusion
Knowledge of the heat sensitivity of oxytocin and the potential impacts of inconsistent cold
storage on product quality is not widespread amongst healthcare providers, policy makers
and supply chain experts in Myanmar, Ethiopia and India. Targeted training and advocacy
messages are warranted to emphasise the importance of cold storage to maintain oxytocin
quality.
Background
Postpartum haemorrhage (PPH) is estimated to cause approximately 20% of global preg-
nancy-related deaths with these deaths occurring overwhelmingly in low and lower-middle
income countries (LMIC) [1]. Oxytocin is recognised by the World Health Organisation
(WHO) as the gold standard therapy for the prevention of PPH and, when delivered as part
active management of the third stage of labour, has been shown to reduce the risk of bleeding
by 66% [2, 3]. However, oxytocin must be stored under cold (2–8˚C) conditions in order to
prevent drug degradation and maintain product quality [4]. Short term excursions outside of
the cold chian are possible without significant loss of product quality, with exposure to 30˚C
for up to one month considered acceptable [4]. A number of oxytocin injection products are
currently available which specify storage below 25˚C, implying that, unlike those which recom-
mend storage between 2–8˚C, these products are heat stable and can be stored under ambient
conditions. However, in order to maintain quality at higher storage temperatures, these prod-
ucts are marketed with a shorter shelf-life. In addition, these products are unsuitable for use in
many LMIC, where hot climates and resource limitations will result in exposure to tempera-
tures greater than 25˚C if products are stored under ambient conditions [5].
Establishing and sustaining a consistent cold chain in resource-limited settings is challeng-
ing. Significant progress has been made towards maintaining stringent temperature-controlled
storage of vaccines, predominantly through the establishment of the Expanded Program on
Immunisation (EPI), a key strategy of which was to develop dedicated cold chain infrastruc-
ture and promote adequate knowledge and practices amongst policy makers and providers [6].
However, similar gains towards managing the storage of oxytocin and other temperature-sen-
sitive medications have been less substantial. In recent years, advocacy bodies and develop-
ment agencies have directed increasing attention to the importance of controlling oxytocin
storage conditions to preserve product quality. The recent release of a joint statement by the
WHO and UNICEF endorsing inclusion of oxytocin and other temperature sensitive drugs
and medical products in the EPI cold chain is a significant step and should be strongly
endorsed [7].
While policy dialogues around oxytocin storage have intensified amongst international
health organisations, national guidelines in many LMICs often contain limited or varied infor-
mation on oxytocin storage conditions. Oxytocin is listed on the essential medicines list for
110 out of 122 countries surveyed by the Reproductive Health Supplies Coalition [8], however,
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guidelines for drug storage are rarely included in these policy documents. In some countries,
drug storage requirements are published in a national medicines formulary, however, guide-
lines for oxytocin storage are varied or limited. For example, storage of oxytocin at 2–8˚C is
recommended in the national formularies of Ethiopia [9] and Kenya [10], while the national
formulary of India specifies storage below 30˚C [11] and no guidance is provided in the for-
mulary of Bangladesh [12], Nigeria [13], Nepal [14] or Zambia [15].
Over the past 25 years there have been several reports on oxytocin quality in LMIC, with
the majority of publications released in the last five to seven years. The scale and scope of these
studies range from collection and analysis of a handful of ampoules [4, 16], to large-scale post-
marketing surveillance studies [17–20]. A recent systematic review has consolidated the evi-
dence emerging from these studies and highlights that the quality of oxytocin ampoules avail-
able in LMICs is severely compromised, with more than half (57.5%) of ampoules collected in
Africa and almost a quarter (23.3%) of ampoules in Asia failing to meet international quality
specifications [21].
Despite the increasing body of literature emerging on oxytocin quality, less is known about
the awareness of stakeholders involved in oxytocin supply, storage and use towards the impor-
tance of maintaining a consistent cold chain for oxytocin or their perceptions of the quality of
product available. Therefore, a qualitative study was conducted in Myanmar, India and Ethio-
pia to explore the knowledge of healthcare providers, policy makers and supply chain experts
about oxytocin stability and storage requirements. Their perceptions of oxytocin quality and
experiences of barriers that exist to cold chain maintenance were also explored.
Methods
Methods are reported according to the consolidated criteria for reporting qualitative research
(COREQ) framework [22].
Study design
An explorative qualitative study was conducted, where data was collected through Focus
Group Discussions (FGDs), In-Depth Interviews (IDIs) and direct observations at healthcare
facilities. FGDs were conducted to explore group norms and derive in-depth information
through interactions between participants. IDIs were conducted to engage individuals with
specialist knowledge and in circumstances where there was limited availability of participants
(e.g. Ministry of Health stakeholders, specialist clinicians). Direct observations were conducted
at healthcare facilities to triangulate responses from participants about oxytocin storage prac-
tices and cold chain infrastructure.
Research team and reflexivity
In each country, a local principal investigator oversaw all aspects of the research, in collabora-
tion with a project coordinator, who was responsible for assuring consistency of approach
across territories. Data was collected by researchers with experience in qualitative research
methods and a thorough understanding of the local context. All researchers were trained in
the background and objectives of the study and given a refresher training on qualitative
research methodology and research ethics. There was no pre-existing relationship between the
participants and any researchers involved in data collection. Adjustments were made to vocab-
ulary, tone and body language in order to minimise the impact of any power differentials
between researchers and participants due to gender, social-economic status, or education.
This research was conducted as part of a broader study to understand the acceptability and
feasibility of a novel heat-stable inhaled oxytocin product for the prevention of PPH. The
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findings presented here represent the needs assessment component, where the limitations of
the currently available injectable oxytocin were explored (with particular focus on stakeholder
awareness or perception of limitations). Additional topics that were explored with participants
of this study included knowledge, attitudes and practices towards childbirth and PPH, per-
ceived benefits and concerns regarding an inhaled oxytocin product and the operational feasi-
bility of product introduction into the local health system. In order to minimise response bias,
descriptions of the inhaled oxytocin product were kept brief during the informed consent pro-
cess and only provided in detail after participants’ knowledge and perception of injectable oxy-
tocin had been explored.
Study settings
Research was conducted in Myanmar, India and Ethiopia, which were selected to represent
the regions carrying a high burden of maternal mortality: South-East Asia, South Asia and
Sub-Saharan Africa. Maternal health in Myanmar has improved significantly over the past
decade, however, the country’s maternal health indicators remain amongst the poorest in the
South-East Asian region. With a 2015 Maternal Mortality Ratio (MMR) of 178 deaths per
100,000 live births, Myanmar has failed to meet its Millennium Development Goal 5 target of
130 [23]. Likewise, in India, maternal health indicators still trail those of the developed world.
There were an estimated 45,000 maternal deaths in India alone in 2015, the second largest
number reported for any one country (behind Nigeria), accounting for 15% of the total num-
ber of maternal deaths worldwide [23]. In recent years Ethiopia has seen dramatic improve-
ments in maternal health outcomes, with the MMR declining from 1,400 deaths per 100,000
live births in 2000 to 420 in 2013 [23]. However, with 11,000 maternal deaths in 2015, Ethiopia
remains the fourth largest contributor to global maternal deaths, behind India, Nigeria and the
Democratic Republic of Congo [23].
Recognising that there is significant within country variation in maternal health outcomes
and indicators of health system functioning (including availability and reliability of cold chain
facilities), research was conducted in urban and rural areas of each country to include settings
where a large disparity in resource availability was expected. In Myanmar, research was con-
ducted in urban and rural townships within Yangon region and in a rural township in Magwe
region. In India, research was conducted in the state of Uttar Pradesh, where urban settings
were selected from within Lucknow municipality and Sitapur district, and rural settings were
selected from within Raebareili district. In Ethiopia, in addition to targeting urban and rural
areas, research was conducted in a major region (Oromia) and two emerging regions (Gam-
bella and Afar). Emerging regions (Afar, Somali, Benishangul-Gumuz and Gambella) of Ethio-
pia are well recognised to face particular health, economic and conflict-related hardships.
Compared to the rest of the country, emerging regions score poorly on key maternal health-
care service indicators, such as overall readiness of facilities to provide routine delivery care (a
composite score which comprises infrastructure, human resource and drug availability indica-
tors) [24].
Participant sampling
Participants of this study were healthcare providers involved in the use and storage of oxytocin
including, nurses, midwives, doctors, obstetricians/gynaecologists and pharmacists. Key infor-
mants who played a role in oxytocin policy and supply were also engaged, including supply
chain experts, Ministry of Health officials, and representatives from non-government organi-
sations (NGOs) and professional associations. In order to explore knowledge and practice
across the healthcare spectrum, healthcare providers were purposively sampled across a range
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PLOS ONE | https://doi.org/10.1371/journal.pone.0203810 September 25, 2018 4 / 16
of cadres (including community health volunteers through to obstetricians), from a range of
health facility tiers (including health posts or sub-centres through to tertiary hospitals) in
urban and rural areas of each country. Key informants were purposively sampled based on
their position and experience and were typically engaged from major cities within each study
region. Data were collected until it was felt that data saturation had been achieved. Across Ethi-
opia, Myanmar and India, a total of 158 healthcare providers and 40 key informants were
engaged through 12 FGDs and 106 IDIs (see Table 1). Of the healthcare providers recruited,
the predominant cadres directly involved in oxytocin use, storage and supply were those based
at healthcare facilities (e.g. nurses, doctors, pharmacists). Community-based providers such as
auxiliary midwives (Myanmar), Accredited Social Health Activists (India) and health exten-
sion workers (Ethiopia) were also recruited as they had received some level of training in intra-
partum care and thus had an awareness of oxytocin, although they were not typically directly
involved in the storage and supply of the drug. In Myanmar, the role of community-based pro-
viders (auxiliary midwives and midwives) in oxytocin use was found to vary considerably
between villages and thus a relatively high number of FGDs were conducted with these provid-
ers in order to reach saturation of information. Direct observations were conducted at a range
Table 1. Number of FGDs and IDIs conducted for each participant group in each country.
FGDs
(urban, rural)
IDIs
(urban, rural)
Total participants (urban, rural)
Myanmar
Auxiliary midwives 4 (1, 3) - 29 (8, 21)
Midwives 3 (1, 2) 1 (0, 1) 27 (10, 17)
Nurses, health assistants - 3 (1, 2) 3(1, 2)
Medical officers, township medical officers - 3 (2, 1) 3 (2, 1)
Obstetricians - 5 (5, 0) 5 (5, 0)
Pharmaceutical company representatives - 2 (2, 0) 2 (2, 0)
UN agencies/NGO staff members - 3 (3, 0) 3 (3, 0)
Myanmar total 7 (2, 5) 17 (13, 4) 72 (31, 41)
India
Accredited Social Health Activist 1 (0, 1) - 7 (0, 7)
Nurses - 4 (2, 2) 4 (2, 2)
Doctors/obstetricians - 5 (3, 2) 6 (4, 2)
Pharmacists - 2 (2, 0) 2 (2, 0)
Supply chain experts - 2 (2, 0) 2 (2, 0)
Government officials - 2 (2, 0) 2 (2, 0)
Pharmaceutical company representatives - 1 (1, 0) 1 (1, 0)
UN agencies/NGO staff members - 2 (2, 0) 3 (3, 0)
India total 1 (0, 1) 18 (14, 4) 27 (16, 11)
Ethiopia
Health extension workers 1 (1, 0) 8 (2, 6) 17 (11, 6)
Nurses, midwives, health officers 2 (2, 0) 22 (11, 11) 34 (23, 11)
Doctors/obstetricians - 11 (9, 2) 11 (9, 2)
Pharmacists - 10 (5, 5) 10 (5, 5)
Supply chain experts - 8 (6, 2) 9 (7, 2)
Government officials - 8 (5, 3) 9 (6, 3)
NGO and professional associations representatives 1 (0, 1) 4 (3, 1) 9 (3, 6)
Ethiopia total 4 (3, 1) 71 (41, 30) 99 (64, 35)
Grand total 12 (5, 7) 106 (68, 38) 198 (111, 87)
https://doi.org/10.1371/journal.pone.0203810.t001
Knowledge, perception and practice towards oxytocin quality in resource-limited settings
PLOS ONE | https://doi.org/10.1371/journal.pone.0203810 September 25, 2018 5 / 16
of health facility tiers involved in the provision of maternal health services, including health
posts, health centres, hospitals, and private clinics. Direct observations were conducted at total
of 51 healthcare facilities (see Table 2).
Data collection
Data was collected in Myanmar from June 2015 to February 2016, in India from October 2015
to February 2016, and in Ethiopia from April 2016 to August 2016. Written informed consent
was obtained from all participants on the day of their involvement in the study, before com-
mencing each FGD or IDI. Each FGD and IDI was conducted in a space that offered sufficient
privacy and convenience for participants, such as private offices, community centres or private
homes. FGDs consisted of between five and 12 participants. Typically, one participant at a
time was engaged for IDIs, however, in some cases two respondents were interviewed together
(at the suggestion of the participant and when it was felt by researchers that this approach
would enhance data collection). During IDIs and FGDs, responses from participants were elic-
ited by an experienced moderator using a semi-structured interview guide. The content of
interview guides was consistent between study countries, however, the format and wording of
guides was pilot-tested, adapted to suit the local context and translated into the local language.
Guides were designed to be sufficiently prescriptive yet flexible such that they covered all nec-
essary research domains, while allowing researchers to explore novel topics emerging during
discussion.
Table 2. Number of direct observations conducted at healthcare facilities in each country.
Facility type Obstetric care
capability
Facilities observed (urban,
rural)
Myanmar
Sub-centre Dispensary/ANC 1 (0, 1)
Rural health centre / maternal & child health centre Dispensary/ANC 2 (0, 2)
Township hospital CEmOC 2 (2, 0)
District, general or central hospital CEmOC 3 (3, 0)
Private clinic / hospital CEmOC 2 (2, 0)
Myanmar total 10 (7, 3)
India
Urban health post Dispensary/ANC 1 (1, 0)
Primary health centre BEmOC 2 (0, 2)
Community health centre / maternal & child health
centre
BEmOC 3 (2, 1)
Tertiary hospital CEmOC 1 (1, 0)
Private clinic CEmOC 1 (1, 0)
India total 8 (5, 3)
Ethiopia
Health post Dispensary/ANC 5 (0, 5)
Health centre BEmOC 16 (9, 7)
Hospital CEmOC 6 (4, 2)
Private or joint public / private CEmOC 6 (4, 2)
Ethiopia total 33 (17, 16)
Total 51 (29, 22)
ANC = Antenatal clinic; CEmOC = comprehensive emergency obstetric care; BEmOC = basic emergency obstetric
care.
https://doi.org/10.1371/journal.pone.0203810.t002
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Where consent was provided by participants, FGDs and IDIs were audio recorded using
digital recorders. At least one note taker was present at each FGD and IDI to document non-
verbal observations and keep a record of the content of the discussion (to complement audio
recordings and/or serve as a back-up in case audio was not successfully recorded). FGDs and
IDIs were drawn to a close at the point when researchers felt that discussion guides and emer-
gent topics were adequately explored (or earlier if availability of the participants’ time was lim-
ited). FGDs lasted for between 40 and 120 minutes, while IDIs lasted for between 20 and 75
minutes. Direct observations were conducted to explore the practices of oxytocin storage and
availability of cold storage infrastructure. Data from observations were recorded using a struc-
tured checklist.
Data management and analysis
Audio recordings from FGDs and IDIs were transcribed verbatim in the local language, sup-
plemented with written notes, and translated into English. English translations were verified
through independent reverse translation. Thematic content analysis was applied, where tran-
scripts from each country were coded by a team of three researchers using NVivo software
(version 11). Each transcript was read by at least two analysts independently and open codes
applied to units of meaning within words, phrases or paragraphs of text. Throughout the cod-
ing process, analysts met regularly to compare codes and develop a standardised coding frame-
work, which was then applied to subsequent transcripts. At the conclusion of coding, intensive
discussions were held among analysts to agree on a final thematic framework. This framework
was discussed and finalised by all in-country research partners at an analysis workshop held at
the conclusion of the study.
Ethical considerations and approvals
This study involved the collection of qualitative data from individuals regarding their knowl-
edge and practices towards oxytocin. While risks to participants were minimal, they included
potential embarrassment or concern about admitting to knowledge or practices that contrast
with global or national guidelines on oxytocin. Thus, measures were put in place to preserve
the privacy, comfort and dignity of all participants. Written informed consent was obtained
from all participants. Participants were assured that their data would be stored securely and
accessible only to authorised researchers, and that no identifying information would be con-
tained in any publications arising from the study. The design and procedures for research in
all three countries were reviewed and approved by the Alfred Hospital Ethics Committee
(Project 153/15) and ratified by the Monash University Human Research Ethics Committee
(CF15/1701–2015000854). The Department of Medical Research approved research in
Myanmar (48/Ethics 2015). The Community Empowerment Lab Institutional Ethics Com-
mittee approved research in India (CEL-IEC/2015003). The Scientific and Ethical Review
Committee of the Ethiopian Public Health Institute approved research in Ethiopia (EPHI
6.13/269).
Results
Analysis of data arising from this study are discussed in the context of three interrelated the-
matic categories: 1) the knowledge and practices of stakeholders towards the storage require-
ments for oxytocin; 2) perceptions of the quality or efficacy of the oxytocin product; and 3)
descriptions of any constraints to reliable cold storage of oxytocin.
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Knowledge and practices around oxytocin storage
In Myanmar, oxytocin was not refrigerated at any of the healthcare facilities visited as part of
the study. Providers also reported that oxytocin is not stored refrigerated in the public supply
chain, either in storage warehouses or during distribution. Notably, oxytocin was stored under
ambient conditions even when a functional refrigerator was available. The most common rea-
son why ambient storage of oxytocin was practiced in health facilities was due to a belief in
these to be the appropriate storage conditions for oxytocin (as was the case for the majority of
nurses, midwives and auxiliary midwives from both urban and rural areas). Some doctors and
obstetricians recognised the requirement for oxytocin to be refrigerated, but explained that
oxytocin is stored under ambient conditions in line with historical practices. One obstetrician
explained that as oxytocin was not refrigerated in the supply chain, and thus there was little
point in keeping it cold in the facility. Another suggested that the need to refrigerate oxytocin
was not a major concern in relation to the other healthcare challenges experienced.
We have to bear so many difficulties and using oxytocin without cold chain is not a big issue at
all for developing countries
- Obstetrician, private clinic, Myanmar
Practices around cold storage of oxytocin in India were varied. In many public sector facili-
ties oxytocin was stored at room temperature both in the pharmacy and in the labour ward,
despite the availability of a functional refrigerator. This included primary healthcare centres
and community healthcare centres in urban and rural areas. In addition, oxytocin was stored
and transported under ambient conditions at a district level supply warehouse. In contrast,
oxytocin was stored refrigerated in a community health centre, a tertiary hospital and a private
clinic in an urban area. Ambient storage of oxytocin was reported to follow manufacturers’
guidelines, and all of the oxytocin brands observed at public healthcare facilities were labelled
for storage ‘in a cool dry place’, leading providers to believe that storage at room temperature
is sufficient.
[Storage instructions specify] only cool and dark place, that's all! Temperature maintenance is not
given. Fifteen years back even I was not knowing that this (oxytocin) is kept in the refrigerator
- Obstetrician, private clinic, India
Almost all healthcare providers engaged in Ethiopia expressed their knowledge of the
requirement for oxytocin to be stored refrigerated. This included health extension workers,
nurses, midwives, pharmacists and obstetricians from both urban and rural areas across major
and emerging regions. Many respondents explained that the oxytocin product will lose efficacy
if it has not been kept refrigerated and therefore expressed their attitude that cold storage of
the drug is not only a requirement in standard protocols, but highly important.
Normally the medication (oxytocin) should be stored inside refrigerator from the production
site up to the site of use. . .while it is stored out of refrigerator it reduces the effectiveness of
medication (the effectiveness of oxytocin is reduced after storage outside of the refrigerator).
- Health extension worker, health post, Ethiopia
Accordingly, during IDIs, almost all healthcare providers reported that the drug is stored
refrigerated at the facility at which they work. Many providers also reported that oxytocin is
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delivered refrigerated. However, data from direct observation at healthcare facilities indicated
that the storage practice for oxytocin is more varied. Oxytocin was observed to be stored out-
side of the refrigerator in the labour wards of approximately one third (seven out of 21) of the
healthcare facilities where this data was collected (five urban facilities and two rural). In some
cases, observation of oxytocin storage conflicted with reports given by healthcare providers
during IDIs. For example, at a hospital where an obstetrician and a nurse reported that oxyto-
cin is stored refrigerated, only a small batch of ampoules (the daily supply) were kept in the
refrigerator, whereas the rest of the stock was stored at room temperature. With the exception
of this hospital, oxytocin was stored refrigerated when refrigerators were available at all other
facilities where this data was collected.
Perceptions of oxytocin quality
A prominent theme during discussions with some healthcare providers in Myanmar was the
perception that the oxytocin injection used in practice has impaired effectiveness. Although
these reports were not heard from nurses, midwives or auxiliary midwives, doctors and obste-
tricians described their experiences with unsatisfactory responses to oxytocin. To overcome
perceived failings in oxytocin efficacy, high doses were reportedly administered for PPH treat-
ment (up to 150 IU in contrast to WHO recommendations of 40 IU[3]).
Maybe 20 unit or 40 unit or 80 unit or sometimes 100 unit. In the WHO recommendation is
to give oxytocin, for example, 20 units in 1 litre of normal saline. . .but here we usually give in
500 cc of normal saline we add 20 unit, if nothing happen then we add 40 unit, sometimes we
add up to 80 unit. . . So this is a problem. In our country the oxytocin dosage is very much
higher than the recommended dose.
- Obstetrician, private clinic, Myanmar
In addition, other uterotonics (such as misoprostol) were reportedly used in conjunction
with oxytocin for prevention of PPH, a practice that was perceived by the respondent to be
necessary due the sub-standard quality of the oxytocin product used. In most instances, the
impaired efficacy of oxytocin was attributed to poor quality brands, where products from
India and China were perceived as inferior. Some obstetricians speculated that improper stor-
age also contributed to a decrease in the potency of the injectable product used.
Amongst healthcare providers engaged in India there was limited perception of the oxyto-
cin product being of poor quality or having impaired effectiveness. Most obstetricians
expressed their complete satisfaction with the quality and effectiveness of the oxytocin product
they use. Others conceded that sometimes PPH occurs despite prophylactic administration of
oxytocin but did not attribute this to a sign of compromised product quality. In contrast, an
NGO program officer perceived there to be a decrease in the quality of oxytocin due to
improper storage, in one instance leading to an adverse health outcome.
I had noticed one case in the peak of summer, the oxytocin was kept in the labour room which
was very, very hot and it did not work and the PPH actually happened.
- Program officer, maternal health NGO, India
In Ethiopia, the majority of providers could not recall a time when oxytocin showed signs
of impaired efficacy or quality when this question was put to them by researchers. This percep-
tion was similar for healthcare providers working in urban and rural areas and was particularly
the case for nurses and midwives. However, a limited number of providers, mostly doctors,
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explained that oxytocin failed to stop bleeding after periods of inconsistent power supply, and
reasoned that this was due to degradation of the drug.
Six or seven months [ago], due to break up of refrigerator our midwife put oxytocin on shelf.
And then it was administered to delivering mothers but couldn`t arrest bleeding. I think this is
quality problem caused by keeping the product on the shelf.
- Doctor, regional hospital, Ethiopia
Similarly, inadequate responses to oxytocin were described in relation to use of the drug for
induction or augmentation of labour. Again, this was reasoned to be, in part, due to ineffective
cold storage of the drug. Two obstetricians remarked on the problems of not knowing whether
the quality of oxytocin has been compromised (due to degradation) and lamented on the pau-
city of published data in this area.
Cold chain constraints
In both urban and rural areas of all study countries, all healthcare provider cadres expressed
difficulties with maintaining a reliable cold chain. In Myanmar, cold storage facilities were
available at hospitals in urban areas and used for the storage of vaccines. However, there were
many descriptions of the constraints or unreliability of cold storage facilities. Reliability of
electricity supply was identified as a problem due to power outages and fluctuation in voltage.
In [township] the electricity is unstable and the range of the voltage also is not stable. Some-
times, it is very high and sometimes it is very low. In the industrial zone the power voltage is
changing all the time.
- Medical officer, township hospital, Myanmar
There was an absence of formal cold storage facilities at healthcare centres visited lower
than the township hospital level. Refrigerators were not available at rural health centres and
sub-centres. In these settings, items can be kept cold for short periods in vaccine transport car-
riers using ice bricks supplied from the nearest township hospital.
In India, cold storage facilities were available in the pharmacies of all health facilities visited
that stocked oxytocin. However, refrigerators were not available in the labour wards of most
facilities (with the exception of a private clinic and a tertiary hospital). Electricity supply was
also reported to be intermittent or lacking, particularly in rural areas.
Electricity here, it comes at 12:00 pm then it goes at 4:00 pm, again it will come at 10:00 pm
and then again it will be available till morning, this is the system.
- Pharmacist, primary health centre, India
One nurse suggested that recent privatisation of the electricity supply had resulted in incon-
sistencies, as hospitals must pay for their own electricity from constrained budgets. While facil-
ities usually have a backup generator, some healthcare providers reported that the generator is
sometimes out of fuel.
The majority of stakeholders engaged in Ethiopia suggested that maintaining appropriate
cold storage of oxytocin is a problem in the supply chain and at service delivery points. This
included a range of healthcare providers and key informants and was an equally prominent
theme between the major region (Oromia) and emerging regions (Gambella and Afar). A key
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informant involved in pharmaceutical procurement suggested that challenges begin at import,
as there is no dedicated cold storage room at the airport for pharmaceuticals. He explained
that cold storage facilities are not available at all of the major public sector distribution ware-
houses and that there is limited space available in existing refrigerators.
The same cold room is competing for different activities. Insulin is there. Oxytocin is there. The
other vaccines are there. All those need the cold rooms and are competing for that limited
space in those warehouses.
- Supply chain manager, Ministry of Health, Ethiopia
The challenge of maintaining a consistent cold chain at healthcare facilities was largely
attributed to the unreliability of the power supply and was a particularly prominent theme
amongst healthcare providers from urban areas. These stakeholders suggested that cold chain
constraints are most severe in rural areas but also faced in urban areas. Interestingly, discus-
sions and interviews with providers from rural areas were more often weighted with sugges-
tions that refrigerated storage is not a significant challenge, with most healthcare providers
stating that back-up generators are available. However, some explained that these were either
not functional, or only turned on for specific, high-need purposes (e.g. for surgical procedures
rather than to power refrigerators), confirming that reliable cold storage is an issue across
rural settings. Additional challenges are presented by the unreliability of refrigerators, particu-
larly in emerging regions where high temperatures occurring during summer months were
reported to compromise the ability of refrigerators to maintain temperatures below 8˚C.
Discussion
Through qualitative inquiry, this study explored the knowledge, perception and practices
toward oxytocin of healthcare providers, supply chain experts and policy-makers in Myanmar,
India and Ethiopia. Knowledge of the requirement for cold storage of oxytocin varied con-
siderably amongst different stakeholders and between the three countries. While there was
widespread understanding of the temperature sensitivity of oxytocin amongst all cadres of
healthcare provider in Ethiopia, this knowledge was mixed amongst the providers engaged in
Myanmar and India and often limited to doctors and specialists. Despite the widespread
knowledge amongst stakeholders in Ethiopia, instructions for oxytocin storage conditions dif-
fer between key national policy documents. The Ethiopian National Formulary specifies stor-
age at 2–8˚C [9], while the Ministry of Health’s standard treatment guidelines for obstetrics
recommends storage between 15–30˚C [25]. Despite these contradictory guidelines, the Ethio-
pian Ministry of Health has demonstrated a strong commitment to ensuring oxytocin quality
and improving PPH outcomes, which may have instilled an understanding of the importance
of oxytocin cold storage across healthcare providers in the country. At the time of data collec-
tion, the Ministry of Health was in the process of establishing a dedicated task force with a
mandate to reduce the country’s PPH mortality rate. In addition, the Ministry recently under-
took and audit of oxytocin storage conditions and cold chain reliability [24] and supported a
post-market surveillance study to investigate oxytocin quality in the public and private health
system (publication in draft).
Previous studies have found that knowledge of oxytocin storage requirements varies
between healthcare providers across many LMIC [26–28]. A qualitative study in India found
that physicians, nurses and pharmacists had varying knowledge on how to store oxytocin, with
some suggesting refrigerated storage is required, others suggesting that ambient temperature is
sufficient [26]. Authors of this study reasoned that these findings illustrate that there is a lack
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of formal training of providers on the storage requirements for oxytocin. Review of national
guidelines corroborate this theory, as recommendations differ considerably. The National Formu-
lary released by the Government of India [11] indicates that oxytocin should be stored below
30˚C, whereas guidelines released by the Federation of Obstetric and Gynaecological Societies of
India [29] specify maintenance at 2–8˚C with short term storage at 30˚C as acceptable.
Practices around oxytocin storage largely mirrored provider knowledge of its storage
requirements. However, in some cases, knowledge of the cold storage requirements for oxyto-
cin did not translate into practice. For example, even the physicians in Myanmar who knew
that oxytocin should be stored refrigerated were storing the drug under ambient conditions
and explained that historical practices of storage were followed with limited concern for the
implication on product quality. Similarly, in Ethiopia, widespread reports that cold storage of
oxytocin was necessary and practiced were not always corroborated by findings from direct
observation at healthcare facilities. While our studies indicated that oxytocin was stored refrig-
erated at approximately two third of facilities visited, a recent report released by the Ethiopian
Ministry of Health found that oxytocin was stored refrigerated in over 90% of facilities [24].
The reason for this discrepancy in findings is unclear and warrants further investigation. More
widely, several reports are emerging which show varied practices for oxytocin storage. A study
conducted in India found that oxytocin was stored at room temperature in most facilities (93–
100%) investigated in two districts in Uttar Pradesh, whereas 79–83% of facilities across two
districts in Karnataka state were storing oxytocin under refrigerated conditions [18]. A study
in Tanzania found that oxytocin was not refrigerated in 21 out of 29 hospitals investigated
[30]. Likewise, oxytocin was typically found to be stored at room temperature in health centres
in Sierra Leone [31]. Similar reports of ambient storage of oxytocin have emerged from Mon-
golia [32], Bangladesh [27] and Nepal [33].
A theme that was common to all countries in this study was the significant barriers to main-
taining a consistent cold chain. Across all countries, this was highlighted to be a significant
challenge in rural areas, Refrigeration facilities were not typically present at primary healthcare
facilities in rural areas such as rural health centres and sub-centres (Myanmar) or health posts
(Ethiopia). These findings are in line with published evidence. For example, a service provision
assessment conducted in Myanmar highlighted that deficits in cold storage facilities were most
significant in rural areas, where 44% of facilities have a cold chain system compared to 90% in
urban areas [34]. In Ethiopia, a functional refrigerator was present at 77% of health centres
according to a recent assessment of obstetric care services [24]. However, the findings of this
study highlight that the effectiveness by which refrigerators can maintain temperatures
between 2–8˚C is sometimes in doubt, particularly in emerging regions with extremely hot cli-
mates. While and rural areas are commonly understood to face the most significant deficits in
cold chain, in this study cold storage systems in urban areas were also reported to be unreli-
able. Inconsistencies in electricity supply were cited in this study as a major barrier to main-
taining an effective cold chain across both urban and rural areas. Contingency resources such
as back-up generators were sometimes reported to be inadequate for overcoming these inter-
ruptions in power supply, as these were in some cases either not functional (due to lack of fuel
or damage) or not used for the purpose of powering refrigerators. The inadequacies of electric-
ity supply have been reported in many LMICs [35–38]. A systematic review of the literature
reporting on electricity access at health facilities in sub-Saharan Africa found that, on average,
74% of health facilities had access to electricity [39]. However only 28% of facilities reported
electricity access to be reliable. Of the facilities where generator functionality was assessed,
only a minority (10–29%) reported that the generator was functional at the time of the survey.
This study revealed interesting insights into provider perceptions on the quality of the oxy-
tocin product. There were several providers in Myanmar who suggested that the oxytocin
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injection used in practice is not as ‘potent’ as it should be, citing the need to use high doses to
effectively manage PPH as a potential indication of compromised product quality. While most
providers attributed the substandard quality of oxytocin to the inferiority of the brand, it is
possible that drug degradation may be a contributing factor given the widespread practice to
store oxytocin under ambient conditions. Similarly, in Ethiopia, there were some providers
who felt that the efficacy of oxytocin has been compromised at times and speculated that this
was due to inadequate cold storage of the drug. It should be noted however, that provider spec-
ulations about impairments to the quality of oxytocin product were typically based on isolated
instances of PPH occurring despite prophylactic administration of oxytocin. Rigorous clinical
trials or retrospective analyses of large data sets would be required to determine whether poor
quality of oxytocin correlates with higher rates of PPH in these settings. In Ethiopia, there are
some published studies which cast doubt on the quality of the oxytocin product, as rates of
failed induction following oxytocin administration are significantly higher in Ethiopia [40, 41]
compared to high income countries [42, 43]. Authors of these studies hypothesised that inter-
rupted cold storage of oxytocin may have led to drug degradation and thereby contributed to
these high rates of failed induction.
Strengths and limitations
A notable strength of this study is collection of qualitative insights into the storage practices
and perception of oxytocin quality amongst different cadres of health care providers. This pro-
vides a nuanced understanding of stakeholder knowledge and perception around these sub-
jects. Given that our aim was to seek in-depth insights, collection of data to quantitate
statistically oxytocin storage practices was beyond the scope of this study, and findings have
been drawn from published literature where available.
Investigation of a range of culturally, politically and environmentally diverse nations and
sub-settings is a strength of this study and enables a comprehensive picture of the knowledge,
attitudes and practice around oxytocin in these settings. However, it is understood that there is
considerable intra- and inter-country variability that limit the direct extrapolation of the find-
ings beyond the regions and countries investigated.
This study is a sub-set of a wider research program seeking to understand the barriers and
enablers to the introduction of a heat-stable, inhaled formulation of oxytocin for the preven-
tion of PPH in resource-limited settings. During FGDs and IDIs, researchers were careful to
explore existing attitudes and practices towards oxytocin before providing an in-depth
description of the inhaled oxytocin product. However, it is possible that participants express-
ing a knowledge and concern for the cold storage of oxytocin may have been influenced after
being informed about the development of a heat stable formulation of oxytocin when consent
was obtained. Direct observations of oxytocin storage practices were performed to triangulate
reports from participants and limit the impact of this form of response bias.
Conclusion
This study provides data to emphasise the challenges associated with maintaining a consistent
and reliable cold chain in resource-constrained settings and describes the perception and expe-
rience of providers towards the quality of oxytocin products available in these contexts. These
insights complement published quantitative data on compromised oxytocin quality and may
help to drive action to address persistent oxytocin quality issues in low-resource settings. In
this respect, adoption of heat stable uterotonics will help to address oxytocin quality issues
caused by cold chain limitations. Additionally, the findings of this study highlight that knowl-
edge of the heat sensitivity of oxytocin or cold chain management of the drug is not uniform
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within or across LMICs. Where deficits exist, training and education campaigns targeted
towards healthcare providers are warranted to improve practices to help assure oxytocin
quality.
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